SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Champions Oncology, Inc. (CSBR)

CSBR RSS Feed
Add CSBR Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 12/3/2016 7:06:10 AM - Followers: 39 - Board type: Free - Posts Today: 0



CSBR.OB - CHAMPIONS BIOTECHNOLOGY, INC.
Website:http://www.championsbiotechnology.com/

Edgar Filings:
http://www.sec.gov/cgi-bin/browse-edgar?company=Champions+Biotechnology&CIK=0001041771&filenum=&State=&SIC=&owner=include&action=getcompany

2200 Wilson Blvd, Suite 102-316, Arlington, VA 22201
703-526-0400

Primary State of Incorporation: Delaware

James Martell, Chairman/President/CEO
James E. McCollam, Secretary

On February 14, 2007, the Registrant agreed to acquire all of the patent rights underlying pending U.S. Patent Application no. 11/673,519 and corresponding international patent application (PCT/US2006/014449) filed under the Patent Cooperation Treaty (PCT), both entitled “Design and Synthesis of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs.” The acquisition represents the commencement of the Registrant’s strategy to develop a biotechnology business based on therapeutic drug candidates among other possible ventures.

The purchase price for the patent rights consisted of an aggregate of up to 550,000 restricted shares of common stock, of which 300,000 restricted shares were issued upon execution of the acquisition agreement and 250,000 restricted shares are issuable upon the issuance of one or patents based on U.S. Patent Application no. 11/673,519. The Registrant has 27,624,658 issued and outstanding common shares and of those, 19,573,000 are restricted common shares.



On January 5, 2007, the Registrant agreed to issue 7,000,000 shares of common stock toDr. David Sidransky, an individual investor, for an aggregate purchase price of $28,000. These securities were issued pursuant to a privately negotiated transaction without an underwriter in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act.

On January 3, 2007, the Registrant agreed to issue 2,500,000 shares of common stock to Dr. Manuel Hidalgo, an individual investor, for an aggregate purchase price of $10,000. These securities were issued pursuant to a privately negotiated transaction without an underwriter in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act.


David Sidransky, M.D.
http://www.cnn.com/SPECIALS/2001/americasbest/science.medicine/pro.dsidransky.html





David Sidransky, M.D., has served as a director of the ImClone Systems, since January 2004. On June 15, 2005, Dr. Sidransky was named Vice Chairman of the Board of Directors. Dr. Sidransky is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine. He is a founder of several private biotechnology companies and has served on scientific advisory boards of many private and publicly traded companies, including MedImmune Inc., Telik Inc., Roche, and Amgen Inc. Dr. Sidransky is also a director of Alfacell Inc. He was formerly on the Board of Scientific Counselors at the National Institute of Dental and Craniofacial Research and a member of the Recombinant DNA Advisory Committee at the National Institute of Health. Dr. Sidransky serves on numerous editorial boards and is Senior Editor of Clinical Cancer Research. In addition, he is a Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. He has over 250 peer-reviewed publications, and has contributed more than 40 cancer reviews and chapters and also has numerous issued biotechnology patents. He has been the recipient of many awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award

Link to David Sidransky's patents:
http://www.google.com/patents?client=firefox-a&lr=&q=David+Sidransky&ie=ISO-8859-1&s....

Manuel Hidalgo, M.D., Ph.D.



-Associate Professor of Oncology at the Johns Hopkins Institute.
-M.D.,University Navarra Medical School, Pamplona, Spain
-Ph.D., Infectious Diseases in Cancer, Univeristy Autonoma, Madrid, Spain
-Fellowship (Medical Oncology) University Hospital “12 de Octubre”, Madrid, Spain
-Research Fellow, University Hospital “ 12 de Octubre”, Madrid, Spain
-Clinical Research Fellow, Cancer Therapy and Research Center, San Antonio, TX
-Board Certification in Medical Oncology
-Clinical Interests: Stomach cancer, Colon and rectum cancers, Pancreas cancer, Biliary Tract cancer, Gallbladder cancer.

Dr. Hidalgo is considered a leading researcher in the development of targeted therapies for the treatment of cancer in patients with solid tumors. His research focuses on optimizing the clinical development of novel treatments by measuring target receptor and molecular anomalies, as well as analyzing the biological activity in tumor and normal tissues of patients treated with specific therapies. Dr. Hidalgo is the Principal Investigator in four new clinical studies started within the last year at the Drug Development Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine.

Link to Manuel Hidalgo's patents:
http://www.google.com/patents?client=firefox-a&lr=&q=Manuel+Hidalgo&ie=ISO-8859-1&sp...

OS: 31,624,658 issued and outstanding common shares
Restricted: 23,573,000
Float: 8,051,658


Transfer Agent: Integrity Stock Transfer, Las Vegas, NV 89120

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

News Items and Filings

 
Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
 

 

BALTIMORE, Sept. 1 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.

By maintaining the fundamental genotypic features of the original human tumor along with the stromal components, the Biomerk Tumorgraft preclinical platform enables identification of the most promising development path for a compound in terms of indication, drug combination, and target patient population. The platform also has the potential to identify gene pathways of response and resistance as well as prognostic molecular biomarkers.

"We are excited to continue the growth of our impressive client base and begin working with one of the most respected global leaders in the discovery and development of novel therapies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "Studies suggest that evaluation of oncology compounds through our Biomerk Tumorgraft platform will lead to more successful and efficient clinical development. The value-added by an optimally targeted, more efficient clinical path can result in cost savings, improved clinical and commercial success and significantly more years of patent life following commercialization."

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.

http://www.championsbiotechnology.com/http://www.personalizedcancertreatment.com/

 


 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~



Weekly Chart




Long Term Chart




Daily Chart

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CSBR
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CSBR News: Current Report Filing (8-k) 11/29/2016 04:16:44 PM
CSBR News: Champions Oncology Reports 50% Revenue Growth, Accelerated Progress on Path to Profitability and Future Role Changes of the S... 11/29/2016 04:15:00 PM
CSBR News: Champions Oncology to Announce Second Quarter Financial Results on Tuesday, November 29, 2016 11/23/2016 10:20:00 AM
CSBR News: Champions Oncology Signs $2 million Contract 11/17/2016 04:05:00 PM
CSBR News: Statement of Changes in Beneficial Ownership (4) 11/16/2016 09:02:37 AM
PostSubject
#2331   http://ih.advfn.com/p.php?pid=nmona&article=73022401 altruism 12/03/16 07:06:10 AM
#2330   Where?? Kev2128 12/03/16 06:44:09 AM
#2329   Nice news... altruism 11/29/16 04:53:12 PM
#2328   I don't own any CSBR yet but I've brewpup 10/02/16 10:00:23 PM
#2327   I think its time for a reversal here. DilutionDan 09/09/16 03:48:38 PM
#2326   CSBR moved to the Nasdaq from the OTC: Renee 08/21/15 05:12:34 PM
#2325   CSBR one for 12 reverse split: Renee 08/07/15 07:18:01 PM
#2324   May 2015 Insiders own 68% ;however, 105M O/S puts MarCap RealGenius 05/15/15 02:03:40 PM
#2323   Data from Study of Champions Oncology TumorGrafts to Milburn D 09/24/14 09:42:56 PM
#2322   The .50 range is looking possible. I PieceofPie 03/02/14 08:00:03 PM
#2321   Hold the train. I'm jumping on tomorrow! derekdomino 01/07/14 09:23:06 PM
#2320   No question. Volume going up, it is like eyedoc 01/07/14 04:48:46 PM
#2319   This is probably the best looking chart I Stockpilot1 01/07/14 03:16:39 PM
#2318   Ahh it was only 7 years ago LOL! MWM 09/13/13 10:15:40 AM
#2317   CSBR sell time to get out before reverse PennyMaker 09/13/13 09:48:55 AM
#2316   PROPOSAL NO. 5 GRANT THE BOARD OF DIRECTORS cjm24 08/20/13 10:43:56 PM
#2315   CSBR closed at 1.25 +.15 (13.6%) on RJS32 08/14/13 04:31:06 PM
#2314   CSBR closed at another 52-week high of 1.13 RJS32 07/01/13 08:24:59 PM
#2313   Stock holders must love the performance of CSBR RJS32 06/27/13 05:19:04 PM
#2312   RJS32 06/17/13 05:19:41 PM
#2311   Champions Oncology Reports Results for the Quarter and Milburn D 06/14/13 03:31:48 PM
#2310   Champions Oncology Reports Changes to Board of Directors Milburn D 03/05/13 08:03:06 AM
#2309   Champions Oncology Reports Successful Outcome From Technology Collaboration Milburn D 02/11/13 08:16:04 AM
#2308   I agree. Insider buying is usually a good RJS32 02/03/13 01:14:40 PM
#2307   Time to buy.. benzdealeror2 02/02/13 12:52:59 PM
#2306   Just in case you haven't seen these inside transactions: RJS32 02/01/13 10:52:35 AM
#2305   ;-) patience... cjm24 01/30/13 10:04:50 PM
#2304   Things are happening... Milburn D 01/30/13 09:48:22 AM
#2303   Very impressive. benzdealeror2 01/10/13 11:01:46 PM
#2302   Interesting Presentation http://yahoo.brand.edgar-online.com/displayfilinginfo. cjm24 01/09/13 09:50:19 PM
#2301   Champions Oncology Reports Financial Results for the Quarter Milburn D 12/13/12 07:19:52 PM
#2300   Champions Oncology Announces Geographic Expansion Milburn D 12/13/12 07:19:12 PM
#2299   Anyone have any thoughts on this stock? cjm24 10/28/12 10:06:42 PM
#2298   Unbelievable...........I guess they are holding true to there beaner17 08/19/12 02:33:45 AM
#2297   Gap Filled...... beaner17 08/19/12 02:27:02 AM
#2296   Champions Oncology Reports Resignation Of Director Milburn D 08/03/12 03:53:03 PM
#2295   Champions Oncology Reports Financial Results for the Year Milburn D 07/18/12 06:40:36 PM
#2294   Champions Oncology Inc. Receives Approval from U.S. Regulatory Milburn D 05/18/12 10:23:33 PM
#2293   What do you think this is about? cjm24 05/15/12 10:01:55 PM
#2291   Champions Oncology Reports Fiscal 2012 Third Quarter Financial cjm24 03/14/12 06:17:11 PM
#2290   Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results Milburn D 12/14/11 08:49:07 PM
#2289   Champions Oncology, Inc. Appoints Executive Vice President and Penny Roger$ 11/01/11 02:34:08 PM
#2288   Lumdus, I agree with your last post. My fred the cpa 07/24/11 10:26:35 AM
#2287   We must all wait until the deal is fred the cpa 07/24/11 10:10:27 AM
#2286   I absolutely agree Lumdus. beaner17 07/22/11 12:14:22 PM
#2285   Hi Fred, lumdus 07/22/11 09:42:15 AM
#2284   I respectfully disagree with you for Lumdus for fred the cpa 07/20/11 06:51:01 AM
#2283   Interesting Press Release... lumdus 07/19/11 08:48:40 AM
#2282   It is my opinion that CSBR has fred the cpa 07/18/11 11:33:54 AM
#2281   I guess that the email that I wrote fred the cpa 07/18/11 09:44:21 AM
PostSubject